Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency

Menopause

Volumn 21, Issue 9, 2014, Pages 952-961

  Guerrieri, Gioia M ^a   Martinez, Pedro E ^a   Klug, Summer P ^a   Haq, Nazli A ^a   Vanderhoof, Vien H ^b   Koziol, Deloris E ^c   Popat, Vaishali B ^b   Kalantaridou, Sophia N ^b   Calis, Karim A ^b   Rubinow, David R ^d   Schmidt, Peter J ^a   Nelson, Lawrence M ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Mood; Primary ovarian insufficiency; Quality of life; Self esteem; Testosterone

Indexed keywords

ANDROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PLACEBO; TESTOSTERONE;

ACNE; ADULT; ANDROGEN THERAPY; ARTICLE; BEHAVIOR DISORDER; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; MOOD; MOOD DISORDER; PIGMENT DISORDER; PREMATURE OVARIAN FAILURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SELF ESTEEM; SIDE EFFECT; SKIN IRRITATION; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CUTANEOUS DRUG ADMINISTRATION; HORMONE SUBSTITUTION; MENOPAUSE; PSYCHOLOGY; PSYCHOMETRY; SELF CONCEPT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MOOD DISORDERS; PRIMARY OVARIAN INSUFFICIENCY; PSYCHOMETRICS; QUALITY OF LIFE; SELF CONCEPT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84906940337     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000195     Document Type: Article

References (52)

1. Nelson LM. Primary ovarian insufficiency. N Engl J Med 2009;360: 606-614.
2. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-1332.
3. Hartmann BW, Kirchengast S, Albrecht A, Laml T, Soregi G, Huber JC. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest 1997; 44:127-131.
4. Schmidt PJ, Cardoso GMP, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006;295:1374-1376.
5. Pal L, Bevilacqua K, Zeitlian G, Shu J, Santoro N. Implications of diminished ovarian reserve (DOR) extend well beyond reproductive concerns. Menopause 2008;15:1086-1094.
6. Kalantaridou SN, Calis KA, Mazer NA, Godoy H, Nelson LM. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. J Clin Endocrinol Metab 2005;90:6549-6552.
7. Papalia MA, Davis SR. What is the rationale for androgen therapy for women? Treat Endocrinol 2003;2:77-84.
8. Kalantaridou SN, Calis KA, Vanderhoof VH, et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2006;86:1475-1482.
9. Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update 2012; 18:405-419.
10. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002;77:660-665.
11. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2005;90:4836-4845.
12. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am 1998;27:989-1006.
13. Burd ID, Bachmann GA. Androgen replacement in menopause. Curr Womens Health Rep 2001;1:202-205.
14. Davis SR, Goldstat R, Papalia MA, et al. Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause 2006; 13:37-45.
15. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 1998;83:2717-2725.
16. Mazer NA. Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. Int J Fertil Womens Med 2002;47:77-86.
17. Khastgir G, Studd J. Hysterectomy, ovarian failure, and depression. Menopause 1998;5:113-122.
18. Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005;90: 1428-1433.
19. Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab 2009;94:4820-4827.
20. Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA 1985;253:2871-2873.
21. Hohlagschwandtner M, Husslein P, Klier C, Ulm B. Correlation between serum testosterone levels and peripartal mood states. Acta Obstet Gynecol Scand 2001;80:326-330.
22. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49:397-409.
23. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
24. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326.
25. Rosenberg M. Society and the Adolescent Self-Image. Princeton, NJ: Princeton University Press, 1965.
26. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1996.
27. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
29. Comstock GW, Helsing KJ. Symptoms of depression in two communities. Psychol Med 1976;6:551-563.
30. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
31. Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry 1983; 140:41-46.
32. Cohen CI, Goh KH, Gustave M. A prospective study of outcome and predictors of subclinical and clinical depression in an older biracial sample of psychiatric outpatients. J Affect Disord 2010;121:204-211.
33. Meeks TW, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in Ba minor[ can Bb major[: a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. J Affect Disord 2011;129:126-142.
34. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841-1853.
35. Ehrmann DA, Rosenfield RL. Clinicial review 10: an endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab 1990;71:1-4.
36. Cremoncini C, Vignati E, Libroia A. Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol. Acta Eur Fertil 1976;7:299-314.
37. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 1985;10:325-335.
38. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160.
39. Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70: 1124-1131.
40. Floter A, Nathorst-Boos J, Carlstrom K, Von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002;5:357-365.
41. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-5233.
42. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
43. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-688.
44. Nathorst-Boos J, Floter A, Jarkander-Rolff M, Carlstrom K, Von Schoultz B. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and psychological general well-being. Maturitas 2006;53:11-18.
45. Schmidt PJ, Luff JA, Haq NA, et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011;96:E278-E287.
46. Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010;67:598-607.
47. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-420.
48. Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a doubleblind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58:529-534.
49. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390-398.
50. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359: 2005-2017.
51. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society clinical practice. J Clin Endocrinol Metab 2006; 91:3697-3710.
52. Kessler RC. Appendix Table 1: lifetime prevalence of DSM-IV/WMH-CIDI disorders by sex and cohort. National Comorbidity Survey; 2005. Available at: http://www.hcp.med.harvard.edu/ncs/ftpdir/table-ncsr-by-gender-and-age.pdf. Accessed September 7, 2006. Development